Atıf İçin Kopyala
HASANOĞLU İ., Guner R., Celik I., KANAT F., Batirel A., TELLİ DİZMAN G., ...Daha Fazla
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.4, ss.880-887, 2022 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
52
Sayı:
4
-
Basım Tarihi:
2022
-
Doi Numarası:
10.55730/1300-0144.5387
-
Dergi Adı:
TURKISH JOURNAL OF MEDICAL SCIENCES
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.880-887
-
Anahtar Kelimeler:
COVID-19, remdesivir, antiviral, treatment, mortality
-
İstanbul Üniversitesi Adresli:
Evet
Özet
Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment.